Detalhe da pesquisa
1.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med
; 382(12): 1112-1123, 2020 03 19.
Artigo
Inglês
| MEDLINE | ID: mdl-32130809
2.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet
; 396(10267): 1994-2005, 2021 12 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33308425
3.
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
JAMA
; 313(12): 1223-31, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-25706092
4.
Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis.
J Int AIDS Soc
; 17(4 Suppl 3): 19793, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25397537
5.
Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents.
J Acquir Immune Defic Syndr
; 61(2): 243-8, 2012 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23007118